GlassScriptPhysician profile
Dat T Huynh
NPI 1033298963
$9,551.52
in general payments reported to CMS, 2019-2025
32 companies · $1,583 in 2025
The $1,583 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,081 · 2020: $692 · 2021: $392 · 2022: $1,055 · 2023: $1,417 · 2024: $2,331 · 2025: $1,583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,330.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,865.20 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Teva Pharmaceuticals USA, INC. | $843.55 | 2023-2024 | Austedo Xr, Uzedy |
| Glaxosmithkline, LLC. | $645.22 | 2022-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbvie INC. | $627.00 | 2019-2025 | |
| Alkermes, INC. | $586.10 | 2019-2025 | Lybalvi, Aristada |
| Janssen Pharmaceuticals, INC | $526.51 | 2019-2023 | Invega Sustenna |
| Allergan, INC. | $508.14 | 2019-2020 | |
| Gilead Sciences, INC. | $396.70 | 2023-2025 | Vemlidy |
| Novo Nordisk INC | $394.28 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Neurocrine Biosciences, INC. | $388.52 | 2019-2024 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $386.00 | 2019-2022 | |
| Lilly USA, LLC | $359.36 | 2023-2025 | Mounjaro, Jardiance |
| Sunovion Pharmaceuticals INC. | $249.99 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $239.94 | 2024-2025 | |
| Nestle Healthcare Nutrition INC. | $182.88 | 2020-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.55 | 2019-2024 | Jardiance |
| Aimmune Therapeutics, INC. | $152.10 | 2025 | Zenpep |
| Edwards Lifesciences Corporation | $135.64 | 2022 | |
| Ibsa Pharma INC. | $126.53 | 2021-2023 | Tirosint, Licart |
| Sanofi-Aventis U.S. LLC | $124.81 | 2025 | |
| Mannkind Corporation | $123.09 | 2019 | |
| Ironwood Pharmaceuticals, INC | $122.63 | 2021-2024 | Linzess |
| Urovant Sciences INC | $116.26 | 2022 | |
| Genentech USA, INC. | $71.17 | 2020-2021 | |
| Madrigal Pharmaceuticals | $61.48 | 2025 | Rezdiffra |
| Novartis Pharmaceuticals Corporation | $36.17 | 2019 | |
| Radius Health, INC. | $29.10 | 2025 | Tymlos |
| Amgen INC. | $23.71 | 2023 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.31 | 2025 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $17.79 | 2024 | Zoryve |
| Merck Sharp & Dohme LLC | $14.64 | 2020 | |
| Sumitomo Pharma America, INC. | $14.15 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dat Huynh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.